Westerkirk Capital Inc. Invests $493,000 in Edwards Lifesciences Corporation $EW

Westerkirk Capital Inc. acquired a new position in shares of Edwards Lifesciences Corporation (NYSE:EW) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 6,300 shares of the medical research company’s stock, valued at approximately $493,000.

A number of other hedge funds have also recently added to or reduced their stakes in EW. Parkside Financial Bank & Trust increased its holdings in shares of Edwards Lifesciences by 9.8% during the second quarter. Parkside Financial Bank & Trust now owns 1,455 shares of the medical research company’s stock worth $114,000 after buying an additional 130 shares in the last quarter. Prosperity Consulting Group LLC boosted its holdings in shares of Edwards Lifesciences by 3.2% during the 2nd quarter. Prosperity Consulting Group LLC now owns 4,304 shares of the medical research company’s stock valued at $337,000 after acquiring an additional 132 shares in the last quarter. NewSquare Capital LLC grew its position in Edwards Lifesciences by 57.8% during the 2nd quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock worth $29,000 after acquiring an additional 134 shares during the last quarter. Empirical Finance LLC increased its holdings in Edwards Lifesciences by 0.6% in the 2nd quarter. Empirical Finance LLC now owns 21,329 shares of the medical research company’s stock worth $1,668,000 after purchasing an additional 134 shares in the last quarter. Finally, Patrick M Sweeney & Associates Inc. raised its position in Edwards Lifesciences by 3.4% in the second quarter. Patrick M Sweeney & Associates Inc. now owns 4,215 shares of the medical research company’s stock valued at $324,000 after purchasing an additional 140 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analyst Ratings Changes

Several research firms recently commented on EW. Stifel Nicolaus lifted their target price on shares of Edwards Lifesciences from $85.00 to $95.00 and gave the stock a “buy” rating in a research report on Friday, October 31st. Wells Fargo & Company lifted their price target on shares of Edwards Lifesciences from $84.00 to $88.00 and gave the stock an “overweight” rating in a report on Thursday, August 7th. Canaccord Genuity Group reissued a “hold” rating and issued a $84.00 price objective (up previously from $81.00) on shares of Edwards Lifesciences in a research note on Monday, November 3rd. Wall Street Zen lowered Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a research report on Monday, September 29th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $95.00 target price (up from $90.00) on shares of Edwards Lifesciences in a report on Friday, October 31st. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $91.39.

Edwards Lifesciences Stock Down 0.7%

Shares of Edwards Lifesciences stock opened at $84.67 on Wednesday. The stock’s 50-day moving average is $80.36 and its 200 day moving average is $78.59. Edwards Lifesciences Corporation has a one year low of $65.94 and a one year high of $87.40. The firm has a market cap of $49.14 billion, a price-to-earnings ratio of 36.50, a PEG ratio of 3.78 and a beta of 0.97. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.00 and a quick ratio of 3.29.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.59 by $0.08. The firm had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.The company’s revenue was up 14.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.67 earnings per share. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. Equities research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,020 shares of the stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $82.55, for a total value of $84,201.00. Following the transaction, the vice president owned 22,002 shares in the company, valued at approximately $1,816,265.10. This represents a 4.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Scott B. Ullem sold 13,000 shares of the business’s stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $83.08, for a total value of $1,080,040.00. Following the sale, the chief financial officer owned 39,898 shares of the company’s stock, valued at approximately $3,314,725.84. This represents a 24.58% decrease in their position. The SEC filing for this sale provides additional information. 0.34% of the stock is owned by corporate insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.